Hadasit Medical Research Services and Development Ltd.

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.

Giuseppina Ortu

Alexander Levitzki

Eyal Yosef Mishani

Yulia Rozen

Aviv Gazit

Iris Ben-David

Thomas Bonasera

Radiolabeled epidermal growth factor receptor tyrosine kinase (EGFR-TK) irreversible inhibitors and their use as biomarkers for medicinal radioimaging such as Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT) and as radiopharmaceuticals for radiotherapy are disclosed.

Radiolabeled irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and their use in radioimaging and radiotherapy

A radiolabeled compound of a formula: ##STR1## is described. R1 and R2 are each independently selected from the group consisting of hydrogen, alkyl, hydroxy, alkoxy, halo, haloalkyl, carboxy, carbalkoxy and salts thereof; and A, B, C and D are each independently selected from the group consisting of a hydrogen and an electron withdrawing group, provided that at least one of A, B, C and D is [18]fluorine.

Epidermal growth factor receptor binding compounds for positron emission

Growing community of inventors

Cambridge, United Kingdom

Giuseppina Ortu